PROTAC approaches against drug-resistant EGFRC797S/L858R/T790M mutants: biological evaluation and SAR studies (2020-2025)
{{output}}
The development of epidermal growth factor receptor (EGFR) C797S/L858R/T790M mutation has become a major barrier to tyrosine kinase inhibitors (TKIs). These mutations reduce the drug binding and increase the adenosine triphosphate (ATP) competition, which cont... ...
